Market Place
Sourcing Support
Bio-Thera Expands LATAM Partnership with Third Biosimilar
16 Dec 2024 //
PR NEWSWIRE
Bio-Thera And Biogen Publish TOFIDENCE Phase 3 Trial Data
11 Sep 2024 //
PR NEWSWIRE
Bio-Thera Starts Integrated Trial For Keytruda Biosimilar BAT3306
25 Jul 2024 //
PR NEWSWIRE
Bio-Thera`s Avastin Biosimilar Avzivi Gets Positive CHMP Opinion
03 Jun 2024 //
PR NEWSWIRE
Bio-Thera`s BAT8006 FR-alpha ADC Clinical Data At ASCO 2024
02 Jun 2024 //
PR NEWSWIRE
Bio-Thera, STADA: Golimumab Biosimilar EU, UK Agreement For BAT2506
28 May 2024 //
PR NEWSWIRE
BTS Receives IND Clearance From FDA to Initiate a Phase II Study for BAT8006
25 Mar 2024 //
PR NEWSWIRE
Bio-Thera Solutions Partners with SteinCares to Market Two Biosimilars in LATAM
18 Mar 2024 //
PR NEWSWIRE
Bio-Thera Announces Initiation of Phase IB / IIA Trial for BAT6026
01 Feb 2024 //
PR NEWSWIRE
FDA Approves Bio-Thera Solutions` Avzivi, a biosimilar referencing Avastin®
07 Dec 2023 //
PR NEWSWIRE
FDA Approves Bio-Thera’s Biosimilar of ACTEMRA
08 Oct 2023 //
PRESS RELEASE
FDA Approves TOFIDENCE™ (tocilizumab-bavi) a Biosimilar of ACTEMRA
08 Oct 2023 //
PR NEWSWIRE
Bio-Thera and Biomm enter licensing deal for ustekinumab biosimilar
19 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
Bio-Thera Expands Partnership with Biomm in Brazil with Addition of BAT2206
16 Jun 2023 //
BUSINESSWIRE
Bio-Thera Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting
14 Apr 2023 //
BUSINESSWIRE
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007
13 Mar 2023 //
BUSINESSWIRE
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008
08 Mar 2023 //
BUSINESSWIRE
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010
06 Mar 2023 //
BUSINESSWIRE
China NMPA Approves Bio-Thera’s BAT1806, A Biosimilar to Actemra® (Tocilizumab)
16 Jan 2023 //
BUSINESSWIRE
Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-?-ADC) and BAT8008
02 Dec 2022 //
BUSINESSWIRE
Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC)
02 Dec 2022 //
BUSINESSWIRE
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306
01 Nov 2022 //
BUSINESSWIRE
Bio-Thera Announces First Patient Dosed in Phase 1 Study for BAT2606
14 Oct 2022 //
BUSINESSWIRE
Bio-Thera Announces Presentation of Recombinant Bivalent Nanoparticle Vaccine
11 Oct 2022 //
BUSINESSWIRE
Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022
27 Sep 2022 //
BUSINESSWIRE
Bio-Thera Begins Dosing in PI Study for BAT8009 for Advanced Solid Tumors
02 Aug 2022 //
BUSINESSWIRE
Bio-Thera Solutions Begins Dosing in PI Study for BAT8006 in Solid Tumors
13 Jul 2022 //
BUSINESSWIRE
Biogen and Bio-Thera Present PIII Data for Tocilizumab Biosimilar Candidate
03 Jun 2022 //
GLOBENEWSWIRE
Bio-Thera doses first subject in Phase I solid tumour antibody trial
10 May 2022 //
CLINICALTRIALSARENA
Bio-Thera Announces First Patient Dosed in Australia for BAT7104 in Solid Tumors
09 May 2022 //
BUSINESSWIRE
Bio-Thera Solutions Announces First Patient Dosed in a Phase 1 Study in BAT6026
30 Mar 2022 //
BUSINESSWIRE
Bio-Thera begins patient dosing in Australia for BAT6021 to treat solid tumours
25 Jan 2022 //
PHARMABIZ
Bio-Thera Solutions begins dosing in Phase I trial of cancer drug
30 Dec 2021 //
CLINICALTRIALSARENA
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6026
29 Dec 2021 //
BUSINESSWIRE
Novartis launches review of Sandoz
27 Oct 2021 //
FIERCEPHARMA
Bio-Thera Expands Partnership with Pharmapark in Russia and other CIS Countries
15 Oct 2021 //
BUSINESSWIRE
Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
08 Oct 2021 //
PRESS RELEASE
Sandoz enters commercialization pact with Bio-Thera Solutions for biosimilar bevacizumab
09 Sep 2021 //
PHARMABIZ
Bio-Thera Solutions Announces Commercialization &License Agreement for BAT1706
08 Sep 2021 //
BIOSPACE
Bio-Thera and Hikma Announce License Agreement for BAT2206 in the US
27 Aug 2021 //
BUSINESSWIRE
Bio-Thera Solutions discovers broad-spectrum SARS-CoV-2 neutralizing antibody
11 Aug 2021 //
PHARMABIZ
Bio-Thera Doses First Patient in Phase III Trial for BAT2206
15 Jul 2021 //
BUSINESS WIRE
Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2506
08 Jun 2021 //
BUSINESSWIRE
Bio-Thera Announces FDA Accepts Biologics License Application For BAT1706
28 Jan 2021 //
BIOSIMILARDEVELOPMENT
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trial for BAT1308
21 Jan 2021 //
BUSINESSWIRE
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of `EuCorVac-19`
21 Jan 2021 //
BUSINESSWIRE
Bio-Thera Solutions Partners With Biomm To Market BAT1706 In Brazil
17 Dec 2020 //
BIOSIMILARDEVELOPMENT
Bio-Thera Solutions Partners With Biomm To Market BAT1706 In Brazil
17 Dec 2020 //
BIOSIMILARDEVELOPMENT
Bio-Thera Solutions Submits Marketing Authorization Application MAA for BAT1706
25 Nov 2020 //
BUSINESSWIRE
Bio-Thera Solutions Submits Marketing Authorization Application MAA for BAT1706
25 Nov 2020 //
BUSINESSWIRE
Bio-Thera Solutions Initiates Phase I Clinical Trial for Biosimilar of Stelara
03 Sep 2020 //
BUSINESSWIRE
Bio-Thera Solutions and BeiGene Announce License, Distribution Supply Agreement
24 Aug 2020 //
BUSINESSWIRE
Bio-Thera Solutions Partners with Pharmapark to Market BAT2506
17 Jul 2020 //
BUSINESSWIRE
NMPA Accepts Bio-Thera Solutions’ Biologics License Application for BAT1706
22 Jun 2020 //
BUSINESSWIRE
NMPA Accepts Bio-Thera Solutions’ Biologics License Application for BAT1706
19 Jun 2020 //
BUSINESS WIRE
Bio-Thera Solutions Launches First Commercial Product, QLETLI in China
10 Jan 2020 //
BUSINESS WIRE
Bio-Thera Announces NMPA approval to Initiate Phase I Trial for BAT2206
04 Dec 2019 //
BUSINESS WIRE
China`s Bio-Thera gets approval for Humira biosimilar
08 Nov 2019 //
REUTERS
